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Ernest J. T. Luiten, MD, PhD, Linetta B. Koppert, MD, PhD, and Marjolein L. Smidt, MD, PhDjjObjective: The aim of this study was to perform a systematic review and
meta-analysis to assess the accuracy of different surgical axillary staging
procedures compared with ALND.
Summary of Background Data: Optimal axillary staging after neoadjuvant
systemic therapy (NST) in node-positive breast cancer is an area of contro-
versy. Several less invasive procedures, such as sentinel lymph node biopsy
(SLNB), marking axillary lymph node with radioactive iodine seed (MARI),
and targeted axillary dissection (a combination of SLNB and a MARI-like
procedure), have been proposed to replace the conventional axillary lymph
node dissection (ALND) with its concomitant morbidity.
Methods: PubMed and Embase were searched for studies comparing less
invasive surgical axillary staging procedures to ALND to identify axillary
burden afterNST in patientswith pathologically confirmed node-positive breast
cancer (cNþ). A meta-analysis was performed to compare identification rate
(IFR), false-negative rate (FNR), and negative predictive value (NPV).
Results: Of 1132 records, 20 unique studies with 2217 patients were included
in quantitative analysis: 17 studies on SLNB, 1 study on MARI, and 2 studies
on a combination procedure. Overall axillary pathologic complete response
rate was 37%. For SLNB, pooled rates of IFR and FNR were 89% and 17%.
NPV ranged from 57% to 86%. For MARI, IFR was 97%, FNR 7%, and NPV
83%. For the combination procedure, IFR was 100%, FNR ranged from 2% to
4%, and NPV from 92% to 97%.
Conclusion: Axillary staging by a combination procedure consisting of
SLNB with excision of a pre-NST marked positive lymph node appears to
be most accurate for axillary staging after NST. More evidence from
prospective multicenter trials is needed to confirm this.
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D e-escalation of axillary surgery in clinically node positive(cNþ) breast cancer patients is a topic of debate. The significant
number of patients with axillary pathologic complete response (ax-
pCR) resulting from increased use of neoadjuvant systemic therapy
(NST) urges the need for a less invasive procedure to replace the
conventional axillary lymph node dissection (ALND) in order to
diminish unnecessary morbidity in patients with ax-pCR.1–3 Seeking
for a less invasive procedure, both prevention of unnecessary mor-
bidity and preservation of oncologic safety are of utmost importance.
Until recently, ALND was routinely performed after NST in
cNþ patients, irrespective of axillary response to NST. Recent
surveys among members of the American Society of Breast Surgeons
as well as Dutch surgeons reported changes in axillary surgery in
cNþ patients treated with NST.4,5 The majority of specialists were
willing to replace ALND by a less invasive staging procedure in
patients with a favorable treatment response. A wide variety of less
invasive staging procedures such as sentinel lymph node biopsy
(SLNB), removal of a marked pathologically-proven positive lymph
node (MARI and MARI-like procedures), or a combination of these
two procedures (eg, targeted axillary dissection) are incorporated in
clinical practice according to local preferences.6–9 These results
denote the lack of consensus on the preferred procedure for axillary
staging after NST in pretreatment cNþ patients. Up to now, it is not
clear which procedure is optimal.
The aim of this review is to provide an overview of different
less invasive procedures for axillary staging after NST in pretreat-
ment cNþ patients, which are currently in use. By evaluating the
accuracy of different less invasive axillary staging procedures, we
aim to determine the optimal procedure for axillary staging after NST
in cNþ breast cancer to safely replace ALND.
METHODS
Criteria for Considering Studies for This Review
This systematic review was performed according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines for diagnostic test accuracy.10 A systematic
literature searchwas performedby the first author (JM) for randomized
controlled trials, cohort studies, and case-control studies testing less
invasive axillary staging procedures after NST in cNþ breast cancer
patients treated with NST. Studies were only included if nodal
positivity was pathologically confirmed before starting with NST.
Any study in which a less invasive axillary staging procedure was
compared with the gold standard, that is, ALND,was included. In case
completion ALND (cALND) was not performed routinely, studies
were not considered for quantitative analysis. If relevant studies
included both cN0 and cNþ patients, only the cNþ patients were
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consisted of patients with pathologic confirmed nodal positivity, only
the pathologically confirmed cNþ patients were considered for anal-
ysis. When it was not possible to discriminate between cN0 and cNþ
patients or between pathologically confirmed and non-pathologically
confirmed cNþ patients, studieswere excluded.Reviews, case reports,
conference abstracts, and editorials were excluded. In case of inclusion
of the same study population in 2 or more papers, the most extensive
paper was included. Studies reporting small study populations (10
patients or less) and studies inwhich nodal positivitywas confirmed by
SLNB before NST were excluded. The primary outcome was the
overall ax-pCR rate and the accuracy of the studied less invasive
axillary staging procedure. Studieswere therefore excluded if reported
data did not allow construction of a 2 x 2 contingency table with
absolute numbers of true positive (TP), true negative (TN), false-
positive (FP), and false-negative (FN) test results. FP is always 0, as the
index test and reference test are considered the same in case of a
positive index test result (ie, presence of residual axillary disease). The
secondary outcomewas the identification rate (IFR) of the studied less
invasive axillary staging procedure.
Search Methods for Identification of Studies
The following electronic databases were searched until April
20, 2018, with no restriction on language or date of publication:
Medline (via PubMed) and EMBASE (via EMBASE.com).
A health sciences librarian was consulted to help develop a
detailed search strategy. Details of the full search strategies in both
databases are provided in Appendix 1. The reference lists of included
studies and existing reviews were manually checked for additional
relevant studies.
Selection of Studies and Quality Assessment
Duplicate references were identified and removed with End-
note. Titles and abstracts of all remaining references were scanned
independently by 2 authors (JS and TvN). Subsequently, these 2
authors independently assessed the full text papers of all potentially
eligible studies. Disagreement was resolved by mutual consensus.
Eligible studies were assessed for quality using the Quality
Assessment of Diagnostic Accuracy Studies 2 (QUADAS- 2) ques-
tionnaire.11 The QUADAS-2 was tailored to our analysis, as
described in the guideline. Finally, all included studies were evalu-
ated for quality by the 2 independent authors.
Data Extraction and Analysis
For each included study, the following parameters were
extracted: first author, year of publication, type of hospital, study
design, sample size, characteristics of trial participants (including
primary tumor type, TNM-stage, type of evaluation of axillary
involvement, and NST regimens), type of less invasive axillary
staging procedure after NST and characteristics of the procedure,
type of pathological assessment of lymph nodes (including use of
immunohistochemistry (IHC), definition of ax-pCR, ax-pCR rate,
accuracy, and IFR of the less invasive axillary staging procedure.
For each less invasive axillary staging procedure, the ax-pCR
rate, IFR, false-negative rate (FNR), and negative predictive value
(NPV) were calculated. Rate of ax-pCR was based on data of the
contingency tables. The IFR was defined as the number of successful
procedures divided by the total number of patients in whom the
procedure was attempted. The FNR was defined as the number of
FN divided by the total number of patients with presence of residual
axillary disease [FN / (FNþTP)]. TheNPVwas defined as the number
of TN divided by the total number of patients with a negative test result
[TN / (TN þ FN)]. As FP cannot occur, numbers of TP, TN, and FN
were documented for each procedure and FP was always documented
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.to be 0 (in case FPwas reported to be> 0 in the record, this numberwas
added up to the TP number). Statistical analysis was performed with
Stata/SE Statistical Software for Windows, version 14.2 (StataCorp
LP, College Station, TX). To calculate pooled proportions for ax-pCR
rate, IFR and FNR random-effectsmodels formeta-analysis were used
with 95% exact confidence intervals (CIs) with help of the metaprop
command.12 All considered outcomes are presented in forest plots
including pooled estimates. Chi-squared test was performed to test for
statistical heterogeneity and was quantified by I2-index.13 As recom-
mended in the Cochrane Handbook for Diagnostic Test Accuracy
Reviews,14 reporting bias (eg, publication bias) was not assessed.
Subgroup analyses were performed to evaluate the impact of
several factors on FNR. Factors that were considered relevant were
number of examined lymph nodes, sampling method for SLNB, ycN
status, definition of ax-pCR, and use of IHC in addition to standard
H&E evaluation. Statistical significance was considered as P values
(2-sided)  0.05.
RESULTS
Study Selection
In total, 1920 records were identified through database searching
and reference checking. After deduplication, 1132 records were screened,
which resulted in the selection of 116 records for retrieval of full texts.
Assessment of full text for eligibility yielded 27 records for qualitative
synthesis; a total of 20 records were included in quantitative synthesis.
See Fig. 1 for a flow chart depicting the study selection process.
Study Characteristics
Index Tests
Three different axillary staging procedures were identified:
SLNB, excision of a pretreatment marked biopsy-proven positive
lymph node (hereinafter all such procedures are referred to as ML),
and a combination procedure involving both SLNB and ML. A total
of 2217 patients were included (2002 for SLNB, 95 for ML, 120 for
the combination procedure) in whom the axillary staging procedure
was successful and followed by cALND. See Table 1 for general
characteristics of all studies included for qualitative analysis.
Reference Tests
In 20 studies, the axillary staging procedure was always
followed by ALND as part of trial protocol. A total of 17 trials
investigated accuracy of SLNB,15–31 1 trial investigated ML,8 and 2
trials investigated a combination procedure.6,32
Studies validating the combination procedure were scarce, yet
several studies did report on cohorts of patients in whom a combi-
nation procedure was performed without routine cALND. Therefore,
we decided to include these studies, 7 in total, in the qualitative
analysis.7,33–38 See Table 2 for detailed characteristics of these
studies. In this table, we have included results of a study by our
own research group (manuscript submitted). As cALND was not
routinely performed in these studies, they were excluded from
quantitative analysis.
Risk of Bias and Applicability
Figure 2 shows the methodological quality of all included
studies. In general, studies included in the quantitative analysis
showed a lower risk of bias than studies included only in the
qualitative analysis.
Results of Individual Studies Included in
Quantitative AnalysisPooled Prevalence of ax-pCR
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FIGURE 1. Flow diagram depicting the study selection process.
Simons et al Annals of Surgery  Volume 269, Number 3, March 2019The overall prevalence of ax-pCR in all 20 included studies was
37% (seeAppendix 2). The I2-statisticwas 57.08% (P< 0.01). Test for
heterogeneity between subgroups based on staging procedure was not
significant, supporting the pooling of all studies in 1 overall rate.
SLNB
The IFR of SLNBwas available for 16 of 17 studies. The overall
IFRwas 89% ina pooled sampleof 2154patients (seeAppendix 3). For
all studies, data to calculate FNR andNPVwere available for a total of
2002 patients. An overall FNRof 17%was found (see Fig. 3) andNPV
ranged from 57% to 86% (see Table 3 SLNB). The I2 statistic revealed
values of variation due to heterogeneity of 68.3% for IFR and 38.7%
for FNR (P < 0.01 and P ¼ 0.05, respectively).
Ten studies documented the definition of ax-pCR: overall
FNR was 16%when ax-pCR was defined as ypN0 and 17%when ax-
PCR was defined as ypN0/itcþ (P¼ 0.61, 1 study defined ax-pCR as
ypN0/itcþ/miþ). FNR was reported for single versus dual-tracer
sampling separately in 5 studies and another 6 studies used either
single-tracer or dual-tracer sampling in 100% of patients. Pooled
FNR was 13% for dual-tracer sampling and 16% for single-tracer
sampling (P¼ 0.53). A total of 14 studies reported on the use of IHC:
overall FNR was 15% when IHC was used (either always or in
434 | www.annalsofsurgery.comselected patients) versus 17% when IHC was not used (P ¼ 0.47). In
6 studies, FNR was reported separately in relation to the number of
SLN(s): all 6 studies reported FNR for excision of 3 or more SLNs
(NB: in 1 study, this was 2 or more SLNs) and 5 of 6 studies also
reported FNR for excision of <3 SLNs. Overall FNR was 8% with
removal of at least 3 SLNs and 22%with removal of< 3 SLN(s) (P<
0.0001). In 7 studies, only cNþ patients with ycN0 status were
included. In addition to these studies, another 4 studies reported on
FNR separately for patients with any ycN status versus ycN0 status.
Overall FNR was 14% when only patients with ycN0 status were
taken into account versus 18% when patients irrespective of ycN
status were taken into account (P ¼ 0.14).
ML
One study reported on aML procedure: this study involved the
validation of the MARI procedure (marking axillary lymph nodes
with radioactive iodine seeds) in 95 patients. In this study, the
pathologically proven positive lymph node was marked with an I-
125 seed pre-NST. After completion of NST, at the time of surgery,
the lymph nodewith the Iodine seed was removed. The IFRwas 97%,
the FNR 7%, and the NPV 83.3%. See Table 3 (ML) for character-
istics of this procedure.
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
TABLE 1. General Characteristics of All Studies Included in Qualitative Analysis Sorted by Type of Procedure
First
Author
Year of
Publication
Study
Type
Index
Test
Reference
Test
Sample
Size cN-Stage ycN-Stage
Definition
ax-pCR IHC
Alvarado 2012 R, S SLNB ALND 121 N1-N3 Any NR NR
Boileau 2015 P, M SLNB ALND 127 N1-2 Any ypN0/itcþ Yes, if H&E negative
Boughey 2013 P, M SLNB ALND 637 N1-2 Any ypN0/itcþ No
Brown 2010 R, S SLNB ALND 86 N1-3 Any ypN0/itcþ No
Carrera 2016 P, M SLNB ALND 48 N1-2 ycN0 (MRI þ/- US) NR Yes, always
Enokido 2016 P, M SLNB ALND 130 N1 ycN0 (imaging) ypN0 NR
Ge 2014 P, S SLNB ALND 43 N1-3 Any NR Yes, but not routinely
Kang 2011 R, S SLNB ALND 58 N1-3 Any NR Yes, always
Kuehn 2013 P, M SLNB ALND 123 N1-2 ycN0 (PE þ/-US) ypN0/itcþ No
Ozmen 2010 R, S SLNB ALND 71 N1-2 ycN0 (PE and imaging) ypN0 Yes, if H&E negative
Park 2013 R, S SLNB ALND 169 N1-3 Any ypN0/itcþ Yes, but not routinely
Pinero-
Madrona
2015 P, M SLNB ALND 38 N1-3 Any NR NR
Shen 2007 P, S SLNB ALND 56 N1-3 Any NR No
Thomas 2011 P, S SLNB ALND 26 Nþ ycN0 (PE) NR Yes, always
Yagata 2013 P, S SLNB ALND 81 N1-3 ycN0 (MRI;
including rPR)
ypN0 Yes, if H&E negative
Yu 2016 R, S SLNB ALND 46 Nþ ycN0 (PE) ypN0/itcþ/miþ Yes, always
Zetterlund 2017 P, M SLNB ALND 152 N1 Any ypN0 Yes, but not routinely
Donker 2015 P, S ML ALND 95 N1-3 Any ypN0 Yes, but not routinely
Caudle 2016 R, S Combi ALND 85 N1-3 Any ypN0 Yes, but not routinely
Dashevsky 2017 R, S Combi NA 21 N1-2 NR ypN0/itcþ No
Diego 2016 R, S Combi NA 29 N1 ycN0 (PE) ypN0 Yes, but not routinely
Kim 2017 P, S Combi NA 11 N1-2 Any ypN0/itcþ No
Nguyen 2017 R, S Combi NA 20 N1-3 NR NR NR
Park 2017 P, S Combi NA 20 N1-3 NR ypN0/itcþ Yes, but not routinely
Plecha 2015 R, S Combi NA 19 N1-3 NR NR NR
Siso 2017 P, S Combi ALND 35 N1-3 Any ypN0 Yes, always
Taback 2018 P, S Combi NA 19 N1-2 NR ypN0 NR
Combi indicates combination procedure; H&E, hematoxylin and eosin stain; IHC, immunohistochemistry; M, multicenter; NA, not applicable; NR, not reported; P, prospective; PE,
psychical examination; R, retrospective; rPR, radiologic partial response; S, single-center.
Number of patients in whom the less invasive axillary staging procedure was successful and in whom this procedure was followed by cALND (if applicable).
Annals of Surgery  Volume 269, Number 3, March 2019 Axillary Staging in cNþ Breast CancerCombination Procedure
Two studies investigated a combination procedure: one
involved clipping of the positive lymph node pre-NST later followed
by I-125 seed localization of the clipped node post-NST in
TABLE 2. Characteristics of Studies Involving the Combination Pr
Author
Sample
Size
Pre-NST
Marking
at Time of
FNA/CNB
Pre-NST
Marking
After
FNA/CNB
Post-NST
Marking
Sam
SLN
Dashevsky 21 Clip NA Wire Tc þ
Diego 29 Clip NA Iodine seed Tc þ
Kim 11 Clip NA Wire Tc þ
Nguyen 20 NA Clip Iodine seed Tc a
b
Park 20 NA Charcoal NA Tc a
b
Plecha 19 Clip NA Wire Tc 
Simons (data
submitted)
139 NA Clip/Iodine
Seed
Iodine
seed/wire
Tc a
b
Taback 19 Clip (78.9%) Electromagnetic
Reflector
NA Tc þ
NA indicates not applicable; NR, not reported (a pathologic assessment); Tc, technetiu
Patients who underwent successful ML in combination with SLNB.
yIFR refers to proportion of patients in whom at least 1 lymph node could be identifie
zNumber of lymph nodes of the combination procedure and not the number of lymph
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.combination with SLNB and one involved clipping of the positive
lymph node pre-NST followed by US-guided excision of the clipped-
node in combination with SLNB. Table 3 (Combination) shows
values for FNR and NPV for the 2 combination procedures. As only
ocedure Without Routine ALND
pling
B
IFRy,
%
ML is
SLN, %
Confirmation
Removal ML
Lymph
Nodesz,
Median
(Range)
ALND,
%
Ax-pCR,
%
blue 100.0 NR XR NR 0.0 33.3
blue 100.0 91.0 XR 4 (1–11) 23.3 63.0
blue 100.0 NR XR/
palpation
NR 45.5 36.4
nd/or
lue
100.0 NR XR NR NR NR
nd/or
lue
100.0 75.0 NA 3 (1–12) 60.0 50.0
blue 100.0 100.0 XR/PA 5.7 (mean) NR NR
nd/or
lue
99.3 64.6 XR/PA 2 (1–9) 22.3 36.0
blue 100.0 63.2 XR 4 (2–10) 31.6 31.6
m; XR, specimen radiography.
d with the combination procedure.
nodes of either ML or either SLNB.
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FIGURE 2. Assessment of risk of bias.
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FIGURE 3. Forest plot for the FNR of SLNB.
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performed. The studies appeared clinically similar, as they targeted
the same population in terms of inclusion criteria, definition of ax-
pCR, and use of IHC.DISCUSSION
In this systematic review, the accuracy of 3 different proce-
dures for axillary staging after NST in cNþ patients was evaluated.
This is the first review up to now that compared all these different less
invasive staging procedures with the gold standard ALND. The goal
was to provide an overview of currently available procedures in order
to guide decision making regarding replacing ALND in selected
cNþ patients.
The SLNB for axillary staging after NST in cNþ patients has
been extensively studied over the past years. The SLNB procedure is
widely accepted as axillary staging procedure in cN0 patients. Even
when performed after NST, the accuracy of SLNB for cN0 patients is
accepted.39 SLNB for axillary staging after NST in pre-treatment
cNþ patients, however, is associated with unacceptably high rates of
FNR. In 2015, the accuracy of SLNB in cNþ patients after NSTwas
evaluated in a systematic review that included 8 studies with
40pathologically proven cNþ patients. That review reported an
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.overall FNR of 15% and the NPV of SLNB did not exceed
86%.40 In the current meta-analysis, a total of 17 studies with
2002 patients (the 8 studies of the previous review were also
included) were analyzed. The overall FNR is 17% and the NPV
still does not exceed 86%: in case SLNB predicts ax-PCR, residual
axillary disease is actually missed in at least 1 in 6 patients. The
overall IFR is 89%. Previous studies reported multiple factors that
may improve IFR and accuracy of SLNB, for example, using dual-
tracer sampling technique, evaluating the SLNs with IHC in addition
to standard H&E evaluation and removing 3 or more SLNs. As IHC
and single- versus dual-tracer sampling was not used consistently
within and between studies, it is not possible to draw definite
conclusions from this review on whether/or not specific sampling
and pathologic evaluation methods should be promoted. Our results
did show that FNR was favorable (yet not statistically significant) for
both dual-tracer sampling and pathologic evaluation with IHC. FNR
was also favorable for patients with ycN0 status based on physical
examination and/or imaging compared with any ycN status (FNR of
14% vs 18%, P¼ 0.14). Regarding the number of SLNs, removing
3 lymph nodes was associated with a significantly better FNR in our
meta-analysis (8% vs 22%, P < 0.0001). However, removing  3
SLNs is not achievable in a significant number of patients17 and
whether this will be achieved is unpredictable preoperatively. This
www.annalsofsurgery.com | 437
TABLE 3. Overview and Diagnostic Accuracy Sorted by Type of Procedure
SLNB
Author
Identification
Rate Sampling
SLNs, Median
(range) Ax-pCR % TP FP FN TN
FNR
% (CI) NPV % (CI)
Alvarado 92.7 Tc and/or blue 2 (1–7) 35 57 0 15 39 21 (12–32) 72 (58–84)
Boileau 87.6 Tc and/or blue 2.7 (mean) 35 76 0 7 44 8 (3–17) 86 (74–94)
Boughey 92.7 Tc and/or blue NR 40.0 326 0 56 255 15 (11–19) 82 (77–86)
Brown NR Tc and/or blue 2 (1–10) 30.2 47 0 13 26 22 (12–34) 67 (50–81)
Carrera 90.5 Single radioactive 2.2 (mean) (1–6) 35.4 28 0 3 17 10 (2–26) 85 (62–97)
Enokido 90.9 Tc and/or blue 1.6 (mean) 52 49 0 13 68 21 (12–33) 84 (74–91)
Ge 84.3 Tc and/or blue 2.4 (1–7) 27.9 25 0 6 12 19 (7–37) 67 (41–87)
Kang 87.9 Tc and/or blue 2.8 (mean) (1–8) 28.8 34 0 7 17 17 (7–32) 71 (49–87)
Kuehn 82.6 Tc  blue NR 48.8 51 0 12 60 19 (10–31) 83 (73–91)
Ozmen 92.2 Tc þ blue 2.1 (1–5) 28 44 0 7 20 14 (6–26) 74 (54–89)
Park 94.9 Single, radioactive 2,1 (mean) (1–12) 40.8 78 0 22 69 22 (14–31) 76 (66–84)
Pinero-Madrona 84.0 Tc  blue NR 34.2 15 0 10 13 40 (21–61) 57 (34–77)
Shen 92.8 Tc and/or blue 2 (1–10) 28.6 30 0 10 16 25 (13–41) 62 (41–80)
Thomas 86.7 Single blue 1,57 (mean) (1–4) 31 15 0 3 8 17 (4–41) 73 (39–94)
Yagata 85.3 Tc þ blue 2 (1–7) 37 43 0 8 30 16 (7–29) 79 (63–90)
Yu 95.8 Single: Blue 1,48 (mean) (1–4) 52.2 14 0 8 24 36 (17–59) 75 (57–89)
Zetterlund 77.9 Tc and/or Blue 2 (1–5) 39.5 79 0 13 60 14 (8–23) 82 (71–90)
ML
Author IFR % Pre-NST Marker Post-NST Marker N Lymph Nodes Ax-pCR % TP FP FN TN FNR % (CI) NPV % (CI)
Donker 97 Iodine seed NA 1 26 65 0 5 25 7 (2 – 16) 83 (65–94)
Combination
Author
IFR
%
Sampling
SLNB
Pre-NST
Marker
Post-NST
Marker
N Lymph
Nodes
Ax-pCR
%
ML is
SLN % TP FP FN TN
FNR%
(CI)
NPV%
(CI)
Caudle 100% Tc and/or blue Clip Iodine seed NR 41 77y 49 0 1 35 2 (0–11) 97 (85–1)
Siso NR Tc and/or blue Clip NA 3 median 31.7 77 23 0 1 11 4 (0–21) 92 (62–1)
NA indicates not applicable; NR, not reported; Tc, technetium.
Ax-pCR rate based on data of 2 2 contingency tables.
yRate is based on 134 patients with a clipped node that underwent SLNB (it was documented if the clipped node was identified as an SLN). Eighty-five patients actually underwent
TAD followed by cALND.
Simons et al Annals of Surgery  Volume 269, Number 3, March 2019renders SLNB impractical, as random node-picking should be dis-
couraged. Currently recruiting studies as Alliance 11202 and
NSABP-51/RTOG 1304 will determine whether the SLNB, despite
its rather poor overall accuracy and shortcomings, can have a place in
axillary staging after NST in cNþ patients.41,42
The MARI procedure was the first ML procedure to be
proposed as an alternative to SLNB for axillary staging after NST
in cNþ patients.8 By marking the pathologically proven positive
lymph node before start of NST, it was expected to enable accurate
assessment of treatment response after completion of NST. The
MARI procedure was validated in 1 single-center trial with 95
patients. This study reported an improved FNR (7%), but the
NPV of 83.3% was less favorable, that is, in 1 of 6 patients with
a negative MARI, axillary residual disease is left behind. Therefore,
equally to SLNB, MARI as a stand-alone procedure is insufficiently
accurate to safely replace ALND. Despite the shortcomings of MARI
(potential of missing residual axillary disease and limited evidence
by 1 single—dedicated breast cancer—center trial to support this
procedure), it is already implemented in clinical practice. A recent
publication suggests combining information on axillary burden on
pre-NST PET-CT (ie, number of suspicious lymph nodes:<4 vs 4)
with MARI outcome9 to determine adjuvant axillary treatment: no
further axillary treatment, axillary radiotherapy, or cALND with
axillary radiotherapy. Results of 1 prospective implementation study
showed that this treatment strategy indeed results in a major reduc-
tion of ALND.43 Data of longer follow-up have to determine whether
implementation of this protocol is untimely and whether it does not
438 | www.annalsofsurgery.comonly reduce morbidity but also preserves oncologic safety in terms of
disease-free and overall survival. Prospective trials with sufficient
follow-up are therefore urgently needed.
In the Z1071 trial, a clip was placed in the positive lymph node
before NST in a subset of patients.44 The trial protocol did not require
surgeons to selectively target and remove the clipped node at time of
surgery, but did encourage surgeons and pathologists to document
whether the clipped node was located in the SLNB or ALND
specimen. In 141 of 170 patients with a clipped node, the location
of the clipped node was documented: 75.9% in the SLNB specimen
and 24.1% in the ALND specimen. This suggested that removing the
clipped node together with SLN(s) at time of surgery may improve
accuracy of SLNB and may possibly overcome shortcomings asso-
ciated with SLNB or MARI if used as stand-alone procedures. Up to
now, only 2 trials evaluated accuracy of such a combination proce-
dure and were included in our meta-analysis.6,32 This procedure is
associated with excellent IFRs. Caudle et al6 confirmed that the
clipped node does not necessarily have to be a SLN, as this was the
case in only 77%. Furthermore, FNR is low (2% to 4%) and NPV is
high (92% to 97%). These results are promising: when ax-pCR is
predicted, residual axillary disease is missed in 1 in 12 to 33 patients.
The evidence for this procedure is yet limited with only 2 trials
available (1 retrospective and 1 prospective study), involving small
sample sizes and single-center study designs. The ongoing Dutch
RISAS trial (NCT02800317 at https://clinicaltrials.gov) will prove
whether the promising results of a combination procedure can be
45confirmed in a large, prospective, multicenter trial.
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
Annals of Surgery  Volume 269, Number 3, March 2019 Axillary Staging in cNþ Breast CancerAlthough evidence to support replacing ALND by less inva-
sive procedures is limited, several reports have been recently pub-
lished on implementation of such procedures, especially procedures
involving excision of the ML and SLNs. A variety of methods are
used to target the pathologically proven positive lymph node:
marking with a clip pre-NST followed by placing an iodine seed
or wire in the clipped node post-NST7,33–35,37 and primary marking
with an iodine seed, clip, charcoal, or electromagnetic reflector.36,38
Also, the time of marking the lymph node pre-NST differs: either
immediately at time of FNAC/CNB,7,33,34,37 at a second appointment
once metastatic burden of the punctured lymph node is confirmed by
the pathologist35,36 or even at both occasions.38 Currently, further
research has to define which combination procedure is most accurate,
patient-friendly, and cost-effective. Identification of the ML at time of
surgery is highly feasible, provided that clipping (with/without sec-
ondary localization of the clip) of the node was successful. Success
rates of this part of the procedure are often not sufficiently reported and
may be improved to further optimize combination procedures.
The abovementioned 3 different staging procedures intend to
offer a less invasive strategy compared with the conventional ALND,
yet  10 lymph nodes are removed in some patients with SLNB and
combination procedures. It is important to realize that these proce-
dures serve as a staging procedure to identify ax-pCR and not as a
managing procedure to remove all residual diseases. Hence, it should
be the primary goal to remove as few lymph nodes as possible. In this
way, patients with ax-pCR can truly benefit from less invasive
staging procedures. At the same time, when these procedures identify
axillary residual disease, adjuvant axillary treatment plans should
consist of cALND. Results of the Alliance 11202 and NSABP-51/
RTOG 1304 trials have to be awaited to determine whether cALND
may be replaced by axillary radiation therapy.41,42
As this review is limited by the heterogeneity of included
studies, results of the review should be interpreted with caution. The
random effects model that was used for statistical analysis takes in
account that, although similar interventions were studied, different
populations were included. Factors such as definition of ax-PCR,
sampling method for SLNB, and use of IHC for pathologic assess-
ment of lymph nodes may all impact accuracy of the studied
intervention. These factors differed widely among included studies
and further research is necessary to determine, among others, what
should be the preferred definition of ax-pCR. The prognostic impact
of residual ITCs and micrometastasis may be different for patients
treated in the neoadjuvant compared with adjuvant setting, as they
might be therapy-resistant. A retrospective study of cNþ patients
treated with NAC and always followed by ALND suggested that
patients with residual ITCs and micrometastases carry a similar
prognosis as patients with ypN0.46 These results have yet to be
confirmed in trials where patients with ypN0 and ITCs or micro-
metastasis did not undergoALND. In addition, thevalueof IHChasnot
yet been thoroughly studied, as most studies that used IHC in addition
to standard H&E evaluation, did so randomly, and not in a routine
matter. Contrary to improving accuracy of detecting residual axillary
disease, a potential undesired result of IHC may be detection of
residual disease that would have otherwise been left undetected (of
which implications on prognosis and need for adjuvant treatment are
unknown). The questionwhether IHCmay not only result in improved
accuracy but may also result in overtreatment is yet left unanswered.
In this review, we only included patients in whom cNþ status
was pathologically proven before NST. This is particularly important
to determine true accuracy of the different staging procedures. When
patients who are expected to be cNþ based on physical examination
or imaging only, the number of true negatives rises and the chance to
have false negatives decreases. This may result in a false impression
of improved rates of FNR and NPV.
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.In conclusion, the SLNB as well as ML procedures seem
insufficiently accurate as stand-alone procedures for axillary staging
after NST in cNþ patients. Accuracy of these procedures may
improve by taken in account axillary burden on pre-NST and/or
post-NST imaging. A combination procedure involving excision of
the ML and SLNs appears most accurate for axillary staging and has
the lowest risk of missing axillary residual disease when ax-pCR is
predicted. More evidence from prospective multicenter trials is
needed to confirm this.
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Appendix 1
PubMed search strategy
(‘‘Breast Neoplasms’’[Mesh] OR ((carcinoma OR carcinomas
OR tumor OR tumours OR tumour OR tumours OR neoplasm OR
neoplasms OR malignancy OR adenocarcinoma OR cancer) AND
(breast ORmamma))) AND (‘‘Sentinel LymphNode Biopsy’’[Mesh]
OR sentinel lymph node biopsy OR slnb OR (MARI[tiab]) OR
(Axilla AND staging[tiab]) OR targeted axillary dissection)
AND (sensitivity OR specificity OR ‘‘Sensitivity and Specificity’’
[Mesh] OR ‘‘Predictive Value of Tests’’[Mesh] OR negative predic-
tive value OR positive predictive value OR likelihood ratio OR
diagnosis OR ‘‘false-negative’’ OR ‘‘false-positive’’) AND (‘‘Lymph
Nodes’’[Mesh] OR ‘‘Lymphatic Vessels’’[Mesh] OR ‘‘Lymphatic
Metastasis’’[Mesh] OR ‘‘Lymphatic System’’[Mesh] OR ‘‘Axilla’’
[Mesh] OR axilla) AND ((‘‘Neoadjuvant Therapy’’[Mesh] OR
neoadjuvant OR preoperative OR primary) AND (‘‘Antineoplastic
Agents’’[Mesh] OR chemotherapy OR immunotherapy OR systemic
therapy))
EMBASE search strategy
Search results were restricted to articles, reviews, articles in
press, conference paper, conference review
((breast OR mamma) AND (cancer OR carcinoma OR neo-
plasm OR malignancy OR adenocarcinoma OR ’breast cancer’/exp
OR tumor OR carcinomas OR tumors OR tumour OR tumours))
AND ((’sentinel lymph node biops’ OR slnb OR ’sentinel node’
OR ’sentinel lymph node biopsy’/exp OR ’mari’:ab,ti OR (axilla
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.
Annals of Surgery  Volume 269, Number 3, March 2019 Axillary Staging in cNþ Breast CancerAND staging) OR ’targeted axillary dissection’)) AND (sensitivity
OR specificity OR ’predictive value’ OR ’likelihood ratio’ OR ppv
OR npv OR diagnosis OR ’false negative’ OR ’false positive’) AND
 2018 The Author(s). Published by Wolters Kluwer Health, Inc.((axilla OR lymph) AND (node OR metastasis)) AND ((neo-
adjuvant OR primary OR preoperative) AND (therapy OR immu-
notherapy OR chemotherapy OR systemic))Appendix 2. Forest plot of the ax-pCR rate.ES effect size. The pooled ax-pCR is 37% (33% to 40%).www.annalsofsurgery.com | 441
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